Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a Healthcare company (Biotechnology) with a market capitalization of $236M. The Maz Rating grades it against the other companies in its sector.
Rocket Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.11, Rocket Pharmaceuticals, Inc. trades at 0.7x book value, with an EV/EBITDA of 34.0. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -5.3%, return on invested capital of -49.6% and a free cash flow yield of -67.6%. On the balance sheet: a debt-to-equity ratio of 0.17 and a current ratio of 7.26. Over the past 52 weeks the share price ranged from $2.03 to $5.45, with a beta of 0.49.
Rocket Pharmaceuticals, Inc. does not currently pay a dividend.
19 Wall Street analyst ratings cover the stock: 14 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.